Mission Sells MTX652 to Dimerix in $292M Deal
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Cambridge, UK, July 17, 2026 Mission Therapeutics announced the divestment of its Phase 2-ready USP30 inhibitor MTX652 to Dimerix...
